Efavirenz: A review of the epidemiology, severity and management of neuropsychiatric side-effects

South African Journal of Psychiatry

Volumn 21, Issue 3, 2015, Pages 94-97

  Gaida, R ^a   Truter, I ^a   Grobler, C ^a  

^a NELSON MANDELA METROPOLITAN UNIVERSITY   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; ETRAVIRINE; NEVIRAPINE; RALTEGRAVIR;

ABNORMAL DREAMING; ARTICLE; COMPARATIVE STUDY; CONCENTRATION LOSS; DISEASE SEVERITY; DIZZINESS; DRUG BLOOD LEVEL; DRUG MONITORING; DRUG SAFETY; DRUG USE; GENETIC POLYMORPHISM; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSOMNIA; MANAGED CARE; MENTAL DISEASE; PATIENT CARE; PATIENT MONITORING; PRACTICE GUIDELINE; SIDE EFFECT ASSESSMENT;

EID: 84942354086     PISSN: 16089685     EISSN: 20786786     Source Type: Journal    
DOI: 10.7196/SAJP.8260     Document Type: Article

References (37)

1. Statistics South Africa. Mid-year population estimate. 2013. http://www.statssa.gov.za/publications/P0302/P03022013.pdf (accessed 13 February 2015).
2. AIDS Foundation South Africa. http://www.aids.org.za/hivaids-in-south-africa/(accessed 12 September 2013).
3. Avert: AVERTing HIV and AIDS. http://www.avert.org/hiv-and-aids-treatment-care.htm (accessed 13 February 2015).
4. National Consolidated Guidelines for the Prevention of Mother-to-child Transmission of HIV (PMTCT) and the Management of HIV in Children, Adolescents and Adults. 2014. Pretoria:National Department of Health, 2014.
5. Cavalcante GIT, Capistrano VLM, Cavalcante FSD, et al. Implications of efavirenz for neuropsychiatry: A review. Int J Neurosci 2010; 120 (12):739-745. [http://dx.doi.org/10.3109/00207454.2010.520541]
6. Piscitelli SC. Space out drug discontinuations prior to ‘drug holiday’? Medscape. 2000. http://www.medscape.com/viewarticle/413306 (accessed 1 September 2014).
7. Mukonzo JK, Okwera A, Nakasujja N, et al. Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: A prospective cohort study. BMC Infect Dis 2013; 13 (261):1-11. [http://dx.doi.org/10.1186/1471-2334-13-261]
8. Mukonzo JK, Owen JS, Ogwal-Okeng J, et al. Pharmacogenetic-based efavirenz dose modification: Suggestions for an African population and the different CYP2B6 genotypes. Plos One 2014;9(1):1-9. [http://dx.doi.org/10.1371/journal.pone.0086919]
9. Naidoo P, Chetty VV, Chetty M. Impact of CYP polymorphisms, ethnicity and sex differences in metabolism on dosing strategies: The case of efavirenz. Eur J Clin Pharmacol 2014; 70 (4):379-389. [http://dx.doi.org/10.1007/s00228-013-1634-1]
10. Gutierrez-Valencia A, Viciana P, Palacios R, et al. Stepped-dose versus full dose efavirenz for HIV infection and neuropsychiatric adverse events: A randomized trial. Ann Intern Med 2011;151 (3):149-156. [http://dx.doi.org/10.7326/0003-4819-151-3-200908040-00127]
11. Kenedi CA, Goforth HW. A systematic review of the psychiatric side-effects of efavirenz. AIDS Behav 2011;15(8):1803-1808. [http://dx.doi.org/10.1007/s10461-011-9939-5]
12. Lochet P, Peyriere H, Lotthe A, Mauboussin JM, Delmas B, Reynes J. Long-term assessment of neuropsychiatric adverse reactions associated with efavirenz. HIV Med 2003; 4 (1):62-66. [http://dx.doi.org/10.1046/j.1468-1293.2003.00136.x]
13. Arendt G, de Nocker D, von Giesen H, Nolting T. Neuropsychiatric side effects of efavirenz therapy. Expert Opin Drug Saf 2007;6(2):147-154. [http://dx.doi.org/10.1517/14740338.6.2.147]
14. Nelson M, Stellbrink H, Podzamczer D, et al. A comparison of neuropsychiatric adverse events during 12 weeks of treatment with etravirine and efavirenz in a treatmentnaive, HIV-1-infected population. AIDS 2011;25(3):335-340. [http://dx.doi.org/10.1097/QAD.0b013e3283416873]
15. Journot V, Chene G, de Castro N, et al. Use of efavirenz is not associated with a higher risk of depressive disorders: A substudy of the randomized clinical trial ALIZE-ANRS 099. Clin Infect Dis 2006;42(12):1790-1799. [http://dx.doi.org/10.1086/504323]
16. Deeks SG, Lewin SR, Havlir DV. The end of AIDS: HIV infection as a chronic disease. Lancet 2013;382(9903):1525-1533. [http://dx.doi.org/10.1016/S0140-6736(13)61809-7]
17. Fumaz CR, Munoz-Moreno JA, Molto J, et al. Long-term neuropsychiatric disorders on efavirenz-based approaches: quality of life, psychological issues, and adherence. J Acq Immun Def Synd 2005;38(5):560-565. [http://dx.doi.org/10.1097/01.qai.0000147523.41993.47]
18. Clifford DB, Evans S, Yang Y, Acosta EP, Ribaudo H, Gulick RM. Long-term impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals (ACTG5097s). HIV Clin Trials 2009;10(6):343-355.
19. Clinical Guidelines for the Management of HIV and AIDS in Adults and Adolescents. Pretoria: National Department of Health, 2010.
20. Adco-Efavirenz package insert. Midrand (Gauteng): Adcock Ingram, 2007.
21. Gazzard B, Balkin A, Hill A. Analysis of neuropsychiatric adverse events during clinical trials of efavirenz in antiretroviral-naïve patients: A systematic review. AIDS Rev 2010;12(2):67-75.
22. Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1 infected patients. AIDS 2001;15(1):71-75. [http://dx.doi.org/10.1097/00002030-200101050-00011]
23. Hawkins T, Geist C, Young B, et al. Comparison of neuropsychiatric side effects in an observational cohort of efavirenz- and protease inhibitor-treated patients. HIV Clin Trials 2005; 6 (4):187-196.
24. Gounden V, van Niekerk C, Snyman T, George JA. Presence of CYP2B6 516G> T polymorphism, increased plasma efavirenz concentrations and early neuropsychiatric side effects in South African HIV-infected patients. AIDS Res Ther 2010; 7(32):1-9. [http://dx.doi.org/10.1186/1742-6405-7-32]
25. Lennox JL, DeJesus E, Lazzarin A, et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naïve patients with HIV-1 infection: Amulticentre, double-blind, randomised controlled trial. Lancet 2009; 374(9692):796-806. [http://dx.doi.org/10.1016/s0140-6736(09)60918-1]
26. Orkin C, Nelson M, Katlama C, et al. Changes in patient-reported neuropsychiatric outcomes during the SENSE trial: First-line treatment with two nucleoside analogues plus etravirine or efavirenz. Health Outcomes Res Med 2012; 3(3):113-119. [http://dx.doi.org/10.1016/j.ehrm.2012.06.002]
27. Gutierrez F, Navarro A, Padillo S, et al. Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring. Clin Infect Dis 2005;41(11):1648-1653. [http://dx.doi.org/10.1086/497835]
28. Rihs TA, Begley K, Smith DE, et al. Efavirenz and chronic neuropsychiatric symptoms: A cross-sectional case control study. HIV Med 2006;7(8):544-548. [http://dx.doi.org/10.1111/j.1468-1293.2006.00419.x]
29. Standard Treatment Guidelines and Essential Medicines List for South Africa: Hospital Level Adults. Pretoria: National Department of Health, 2012.
30. Turjanski N, Llyod GG. Psychiatric side effects of medications: Recent developments. Adv Psychiatr Treat 2005;11:58-70. [http://dx.doi.org/10.1192/apt.11.1.58]
31. Treisman GJ, Kaplin AI. Neurologic and psychiatric complications of antiretroviral agents. AIDS 2002; 16(9):1201-1215. [http://dx.doi.org/10.1097/00002030-200206140-00002]
32. Brogan K, Lux J. Management of common psychiatric conditions in the HIV-positive population. Curr HIV/AIDS Rep 2009;6(2):108-115. [http://dx.doi.org/10.1007/s11904-009-0016-x]
33. Ferrando SJ. Psychopharmacologic treatment of patients with HIV/AIDS. Curr Psychiatry Rep 2009; 11(3):235-242. [http://dx.doi.org/10.1007/s11920-009-0036-7]
34. Jonsson G, Joska JA. Assessment and treatment of psychosis in people living with HIV/AIDS. S Afr J HIV Med 2009; 10(3):20-27.
35. Schouten JT, Krambrink A, Ribaudo HJ, et al. Substitution of nevirapine because of efavirenz toxicity in AIDS Clinical Trials Group A5095. Clin Infect Dis 2010;50(5):787-791. [http://dx.doi.org/10.1086/650539]
36. Rossiter D, ed. South African Medicines Formulary. 10th ed. Cape Town: Health and Medical Publishing Group, 2012
37. Claydon P, ed. HIV Treatment Bulletin + South. HIV i-Base 2012;5(1):1-42.